JacobsonKA, GaoZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5:247–264.
2.
CellaiL, CarvalhoK, FaivreE, et al.The adenosinergic signaling: a complex but promising therapeutic target for Alzheimer's disease. Front Neurosci. 2018; 12:520.
3.
CunhaRA. How does adenosine control neuronal dysfunction and neurodegeneration?. J Neurochem. 2016; 139:1019–1055.
4.
Williams-KarneskyRL, SandauUS, LusardiTA, et al.Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest. 2013; 123:3552–3563.
5.
Temido-FerreiraM, FerreiraDG, BatalhaVL, et al.Age-related shift in LTD is dependent on neuronal adenosine A(2A) receptors interplay with mGluR5 and NMDA receptors. Mol Psychiatry. 2018. DOI: 10.1038/s41380-018-0110-9.
6.
CarvalhoK, FaivreE, PietrowskiMJ, MarquesX, Gomez-MurciaV, DeleauA, et al. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in Tau pathology linked to neuronal adenosine A2A receptors. Brain (in press).
7.
OrrAG, HsiaoEC, WangMM, et al.Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015; 18:423–434.
8.
CanasPM, PorciúnculaLO, SimõesAP, et al.Neuronal adenosine A2A receptors are critical mediators of neurodegeneration triggered by convulsions. eNeuro. 2018; 5:pii: ENEURO.0385-18.2018.
9.
ZhaoZA, ZhaoY, NingYL, et al.Adenosine A(2A) receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation. Transl Psychiatry. 2017; 7:e1123.
10.
ChenX, BurdettTC, DesjardinsCA, LoganR, CiprianiS, XuY, et al.Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A. 2013; 110:300–5.
11.
FaivreE, CoelhoJE, ZornbachK, MalikE, BaqiY, SchneiderM, et al. Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer's Disease. Front Mol Neurosci. 2018; 11:235.
12.
LeeCC, ChangCP, LinCJ, et al.Adenosine augmentation evoked by an ENT1 inhibitor improves memory impairment and neuronal plasticity in the APP/PS1 mouse model of Alzheimer's disease. Mol Neurobiol. 2018; 55:8936–8952.
13.
GonçalvesFQ, LopesJP, SilvaHB, et al.Synaptic and memory dysfunction in Abeta amyloid model of early Alzheimer's Disease depends on increased formation of ATP-derived extracellular adenosine. Neurobiol Dis. 2019 [Epub ahead of print]; DOI: 10.1016/j.nbd.2019.104570.
